Brief: Nykode Therapeutics Announces FDA Approval Of Phase 2 Clinical Trial
Sept 5 (Reuters) - Nykode Therapeutics ASA NYKD.OL :
* ANNOUNCES FDA APPROVAL OF IND FOR VB-C-04, A TRIAL OF
VB10.16 IN
HPV16-POSITIVE CERVICAL CANCER
* TO FURTHER ELABORATE ON TRIAL DESIGN AND DEVELOPMENT
STRATEGY AT
UPCOMING CAPITAL MARKETS DAY IN NEW YORK ON SEPTEMBER 20
* IS ON TRACK TO INITIATE TRIAL IN Q4 OF 2023
Source text for Eikon: ID:nObi4l9YTa
Further company coverage: NYKD.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Nykode Therapeutics ASA
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Nykode Therapeutics Mulls Private Placement
Brief: Nykode Receives Draft Recommendation In Tax Case
Brief: Nykode Therapeutics Receives U.S. Vaccine Patent
Brief: Nykode Therapeutics Expects Draft Recommendation From Norwegian Tax Appeal Board In August 2026